Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive res...
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study
of its lead product, CD-NP, for the treatme...
W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry
SEATTLE, Aug. 3 /PRNewswire/ -- Anyone touched by the ravages of cancer knows the rapidly growing, opportunistic cells don't play fair. But in order to expose exactly how cancer cells cheat their host, scientists must first study
the rules governing the orderly cooperation of normal cell...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance o...
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
MONMOUTH JUNCTION, N.J., July 30 /PRNewswire/ -- Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study
NIST scientists study how to stack the deck for organic solar power
A new class of economically viable solar power cellscheap, flexible and easy to makehas come a step closer to reality as a result of recent work* at the National Institute of Standards and Technology (NIST), where scientists have deepened their understanding of the complex organic films at the hea...
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study
and announced plans to provide detailed safety and efficacy...
Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
KEELE, England, July 27 /PRNewswire/ -- A recent independent study
confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics
Company, Biocomposites, ( http://www.biocomposites.com ), as an effective bone
replacement material demonstrating superior bone regenerative properties...
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study
in patients with predominant, persisten...
Oprah, Luke Skywalker and Maradona -- new study investigates how our brains respond to them
Pictures paint concepts of a thousand words- now, for the first time, scientists studying the brain have worked out how words paint concepts in our minds.
The team, including Professor Rodrigo Quian Quiroga at the Department of Engineering of the University of Leicester in the UK, Professor Itz...
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
DALLAS, July 23 /PRNewswire-FirstCall/ -- AC C E S S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , announced today that its European partner, SpePharm , is collecting data from a post approval study
of MuGard in head and neck cancer patients undergoing...
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy
Efficacy and Safety Study
in Patients with Moderate to Severe Post-Operative Pain
SYDNEY, Australia and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-...
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
of alternative drug delivery systems, today reported positive results from a
Phase 2A study
of its oral insulin capsule, ORMD-0801, on type 1 diabetic
Brazil's Scientific Research On The Rise, Thomson Reuters Study Finds
PHILADELPHIA and LONDON, July 13 /PRNewswire/ -- Thomson Reuters today announced the results of a study
documenting Brazil's steady rise during the last two decades in both the volume and impact of its scientific work. According to Science Watch , these findings underscore Brazil's sta...
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced positive results from a 28-week dose-ranging study
of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an ana...
2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process
Immunotec Receives NHPD/Health Canada Authorization to Begin a Study
the Effect of the Cysteine-Rich Whey Protein Isolate (Immunocal(R)) in
Combination with Physical Exercise on Muscle Function, Body Composition
and Inflammatory Cytokine Levels in Elderly Persons: A Randomized,...
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which i...
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
Largest clinical study
ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010
RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 c...
SRNL to study applicability of solar cell coatings
A project under way at the U.S. Department of Energy's Savannah River National Laboratory will study
how special coatings that mimic structures found in nature can increase the usefulness of solar energy as a vital part of the nation's future energy strategy.
Working with Peng Jiang of the Univ...
Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide
AMSTERDAM, June 25 /PRNewswire-FirstCall/ --
- Over 1000 Members of the Research Community View Webcast to Learn About
Findings and New Performance Measurement Method
Elsevier, a world-leading publisher of scientific, technical and medical
information products and services, toda...
Independent U.S. Study Confirms Veritide's Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
--In Testing Conducted by a U.S. Research Institute, Ceeker Correctly Detected Anthrax 100% of the Time--
--Provides First Responders with a Simple and Reliable Tool to Help Quickly Distinguish Public Health Emergencies from Mere Nuisances--
--Study Data to be Presented by Prof. Lou Rei...
New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
SUNNYVALE, Calif., June 24 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today noted that a new article, Evaluation of Universal Antenatal Screening for Group B Streptococcus, published in the June 2009 issue of the New England Journal of Medicine concluded that rapid, PCR-based testing at...
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study
(study 041) of its Phase 3 program in benign prostatic...
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study
in the Phase 3 program with cetrorelix pamoate for the treatment of benign...
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity Study
Indicated Rasagiline Selectivity for Inhibiting MAO-B at Maximum Approved Dose
KANSAS CITY, Mo., June 9 /PRNewswire/ -- Teva Neuroscience, Inc. today presented results from a clinical pharmacology study
in which AZILECT(R) (rasagiline tablets) did not increase the risk of tyramine sensi...
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced results of the Phase 2 study
of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thri...
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day treatment
NEW ORLEANS, June 8 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented results from the first clinical study
of ITCA 650 (DUROS(R) continu...
Diamyd(R) Phase III Study Approved for Younger Patients in the US
STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today
that the company has received approval from the US Food and Drug
Administration (FDA) to include children with type 1 diabetes from 10 years
of age in the company's Phase III study
with the diabetes vaccine Diamyd(R).
Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
JERUSALEM, June 3 /PRNewswire/ -- The Gamida Cell-Teva Joint Venture
announced today that five prestigious cord blood transplantations centers in
Spain, three in Barcelona and two in Valencia, have joined the Excel study.
Participating clinical sites include, in alphabetical order:
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced that additional results from its North American Phase 3 clinical study
of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A...
Document Management Inefficiencies Cost Clinical Study Sites Time, Money
NEW YORK, June 2 /PRNewswire/ -- Document sharing inefficiencies in clinical trials cost investigative sites and study
sponsors time and money, according to a recent online poll by IntraLinks(R), the leading provider of critical information exchange solutions.
The survey revealed heavy...
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio ...
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM
ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ...
YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomiz...
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
First clinical study
evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes
HAYWARD, Calif., May 27 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced it will present clinical data from a phase 1b study
of ITCA 650 (DUROS(R) continuous delivery of e...
Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
CHARLESTON, S.C., May 18 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today they successfully completed the Exploratory Bioequivalence Study
deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
Reykjavik, ICELAND, May 17 /PRNewswire-FirstCall/ -- In a paper published
today in the online edition of Nature Genetics, scientists from deCODE
genetics (Nasdaq: DCGN ) and academic colleagues from Iceland, Denmark and the
Netherlands present the discovery of single letter variations in the ...
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT -
- Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT -
- Conference call and webcast Tuesday, May 19, 6 p.m. PDT -
BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMun...
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
Comprehensive Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive Impact on Vascular Inflammation
SAN FRANCISCO, May 14 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused ...
New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children Study
Presented at the Pediatric Academic Societies Annual Meeting by Vanderbilt University Researchers Shows a Statistically-Significant Association between SpCO and Measures of Lung Function
IRVINE, Calif., May 13 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of P...